Approval · Notice of Compliance 31826 · 2023
PRIVIGEN: Notice of Compliance 31826
Issued October 11, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31826
- Date
- October 11, 2023
- Company
- Csl Behring Canada IncOttawa, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a new manufacturing site for the drug substance
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRIVIGEN | Not yet assigned | — |
Medicinal ingredients
- IMMUNOGLOBULIN (HUMAN) 100 G per L